Sie suchten nach: barr (Englisch - Estnisch)

andrew barr
andrew barr

kirchberg de barr
kirchberg de barr

“financial issues nicola barr
“ rahandusküsimused nicola barr

alsace grand cru followed by kirchberg de barr
alsace grand cru, millele järgneb kirchberg de barr

epstein-barr virus-associated lymphoproliferative disorders
epstein-barri viirusega seotud lümfoproliferatiivsed häired

ebv (epstein-barr virus) lymphoproliferative disease
epstein-barri viirusest (ebv) tingitud lümfoproliferatiivne haigus;

corporate responsibility policy felismino alcarpe ba r b 1 right financial issues nicola barr
ettevõtte vastutuse poliitika felismino alcarpe b a r b 1 ri g h t rahandus nicola barr

denmark was recognised as a protected zone with respect to cryphonectria parasitica (murrill) barr.
taani tunnistati organismi cryphonectria parasitica (murrill) barr suhtes kaitstavaks alaks.

nulojix must not be used in patients who have not been exposed to the epstein-barr virus or in whom previous exposure is uncertain.
nulojixi ei tohi kasutada patsientidel, kellel pole olnud varasemat kokkupuudet epstein-barri viirusega või kelle varasem kokkupuude selle viirusega on ebaselge.

greece has submitted information showing that cryphonectria parasitica (murrill) barr is now established in those regions.
kreeka esitatud teabest selgub, et organism cryphonectria parasitica (murrill) barr. esineb nüüd nendes piirkondades.

in greece, crete and lesvos were recognised as protected zones with respect to cryphonectria parasitica (murrill) barr.
kreeta ja lesbos tunnistati kreekas kaitstavateks aladeks organismi cryphonectria parasitica (murrill) barr suhtes.

27 a variety of innovations, such as techniques for early detection of epstein-barr (ebv) and cmv infections, bone marrow augmentation, the adjunct use of the interleukin-2 antagonist daclizumab, lower initial tacrolimus doses with target trough levels of 10 to 15 ng/ ml, and most recently allograft irradiation were considered to have contributed to improved results in this indication over time (abu- elmagd et al., ann surg 2001; 234:404).
uuenduste mitmekesisus, nagu varajane epstein- barri (ebv) ja cmv infektsioonide avastamine, luuüdi kasvatamine, interleukiin- 2 antagonisti daklisumabi täiendav kasutamine, madalamad takroliimuse algannused madalama toimiva kontsentratsiooniga 10- 15 ng/ ml, ja hiljaaegu siiriku irradiatsioon, aitavad aja jooksul kaasa tulemuste paranemisele selle näidustuse korral (abu- elmagd et al., ann surg 2001; 234: 404).